Literature DB >> 20529801

"I feel like I am 100 years old!" managing arthralgias from aromatase inhibitors.

Loren Winters1, Karleen Habin, Jane Flanagan, Barbara J Cashavelly.   

Abstract

Aromatase inhibitors (AIs) are recommended for the treatment of estrogen-sensitive breast cancer in postmenopausal women and provide a superior risk reduction compared to five years of tamoxifen alone. Arthralgias, a common side effect of AIs, may adversely affect quality of life, treatment adherence, and persistence. Early discontinuation of AIs may result in an inadequate clinical response. Over-the-counter analgesics, exercise, and drug holidays are common strategies used to manage arthralgias, however few interventions are evidence-based. Patients experiencing arthralgias may experience distress and, therefore would benefit from ongoing nursing support. When caring for patients with arthralgias, nurses should assess for potential modifiable risk factors, recommend lifestyle changes and/or pharmacologic interventions, and offer ongoing education and follow-up.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20529801     DOI: 10.1188/10.CJON.379-382

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  8 in total

1.  The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.

Authors:  Victoria K Shanmugam; James McCloskey; Beth Elston; Sandra J Allison; Jennifer Eng-Wong
Journal:  Breast Cancer Res Treat       Date:  2011-11-11       Impact factor: 4.872

2.  Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors.

Authors:  Temitope Olufade; Lisa Gallicchio; Ryan MacDonald; Kathy J Helzlsouer
Journal:  Support Care Cancer       Date:  2014-08-17       Impact factor: 3.603

3.  Development and validation of the Penn Arthralgia Aging Scale among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Laura Lee; Jun J Mao
Journal:  Cancer       Date:  2015-04-29       Impact factor: 6.860

4.  Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Jinbo Chen; Jun J Mao
Journal:  Eur J Cancer       Date:  2018-01-09       Impact factor: 9.162

5.  [Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis].

Authors:  W Eich; W Häuser; B Arnold; W Jäckel; M Offenbächer; F Petzke; M Schiltenwolf; M Settan; C Sommer; T Tölle; N Uçeyler; P Henningsen
Journal:  Schmerz       Date:  2012-06       Impact factor: 1.107

6.  Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors.

Authors:  Justin C Brown; Jun J Mao; Carrie Stricker; Wei-Ting Hwang; Kay-See Tan; Kathryn H Schmitz
Journal:  Breast J       Date:  2013-10-25       Impact factor: 2.431

7.  Post-mastectomy and post-breast conservation surgery pain syndrome: a review of etiologies, risk prediction, and trends in management.

Authors:  Victor E Chen; Benjamin A Greenberger; Zheng Shi; Shefali Gajjar; Wenyin Shi; Waleed F Mourad; Weisi Yan
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

Review 8.  Cholecalciferol and Cancer: Is It a Big D3-eal?

Authors:  Rita Wickham
Journal:  J Adv Pract Oncol       Date:  2012-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.